Su Jin Choi Selected Research

Tyrosine Kinase Inhibitors

1/2011	The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells.
12/2010	Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
7/2010	Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Su Jin Choi Research Topics

Disease

9	Neoplasms (Cancer) 10/2019 - 07/2010
5	Carcinoma (Carcinomatosis) 08/2021 - 01/2011
3	Stroke (Strokes) 08/2017 - 04/2015
3	Lung Neoplasms (Lung Cancer) 01/2011 - 07/2010
2	Immunoglobulin G4-Related Disease 01/2023 - 01/2021
2	Rheumatic Diseases (Rheumatism) 01/2022 - 01/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 07/2010
2	Stomach Neoplasms (Stomach Cancer) 08/2021 - 08/2017
2	Body Weight (Weight, Body) 01/2021 - 01/2014
2	Severe Fever with Thrombocytopenia Syndrome 01/2018 - 07/2017
2	Facial Paralysis (Facial Palsy) 08/2017 - 06/2017
2	Calcinosis 01/2014 - 01/2014
1	Breast Neoplasms (Breast Cancer) 08/2023
1	Glycogen Storage Disease Type II (Pompe's Disease) 01/2023
1	Proteinuria 01/2022
1	Lupus Nephritis 01/2022
1	Retroperitoneal Fibrosis 01/2021
1	Glycogen Storage Disease Type Ix 01/2021
1	Arthritis (Polyarthritis) 01/2021
1	Disease Progression 01/2021
1	Glycogen Storage Disease (Glycogenosis) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Gouty Arthritis 01/2021
1	Hydronephrosis 01/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021
1	Glycogen Storage Disease IIIA 09/2020
1	Glycogen Storage Disease Type III (Cori's Disease) 09/2020
1	Fibrosis (Cirrhosis) 09/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Hyperlipidemias (Hyperlipidemia) 01/2020
1	Chemical and Drug Induced Liver Injury 01/2020
1	Ankylosing Spondylitis 01/2020
1	Infections 10/2018
1	Staphylococcal Infections 10/2018
1	Bacteremia 10/2018
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2018
1	Brain Injuries (Brain Injury) 10/2017
1	Deglutition Disorders (Dysphagia) 10/2017
1	Carcinogenesis 08/2017
1	Neoplasm Metastasis (Metastasis) 03/2016
1	Arteriovenous Fistula 11/2015
1	Hypoxia (Hypoxemia) 09/2015
1	Pathologic Constriction (Stenosis) 05/2015
1	Inflammation (Inflammations) 05/2015
1	Sepsis (Septicemia) 05/2015
1	Thrombosis (Thrombus) 05/2015

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 08/2023 - 08/2017
4	ErbB Receptors (EGF Receptor)IBA 01/2011 - 07/2010
3	DNA (Deoxyribonucleic Acid)IBA 08/2021 - 03/2016
3	Tyrosine Kinase InhibitorsIBA 01/2011 - 07/2010
2	Immunoglobulin G (IgG)IBA 01/2023 - 01/2021
2	Cisplatin (Platino)FDA LinkGeneric 08/2021 - 01/2011
2	GlycogenIBA 01/2021 - 09/2020
2	EnzymesIBA 01/2021 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2018 - 05/2015
2	TabletsIBA 08/2017 - 06/2017
2	Silybin (Lagosa)IBA 03/2015 - 12/2010
2	Gefitinib (Iressa)FDA Link 03/2015 - 07/2010
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2011 - 12/2010
1	human ERBB2 proteinIBA 08/2023
1	Neutralizing AntibodiesIBA 01/2023
1	Bortezomib (Velcade)FDA Link 01/2023
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023
1	Rituximab (Mabthera)FDA Link 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022
1	CreatinineIBA 01/2022
1	Fluorouracil (Carac)FDA LinkGeneric 08/2021
1	CytokinesIBA 01/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	GlucocorticoidsIBA 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	Uric Acid (Urate)IBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	DextrinsIBA 09/2020
1	Complementary DNA (cDNA)IBA 09/2020
1	pullulanase (limit dextrinase)IBA 09/2020
1	Liver GlycogenIBA 09/2020
1	Glycogen Debranching Enzyme System (Glycogen Debranching Enzyme)IBA 09/2020
1	Tumor Necrosis Factor InhibitorsIBA 01/2020
1	QuercetinIBA 10/2019
1	Adenosine (Adenocard)FDA LinkGeneric 03/2019
1	Adenosine A1 ReceptorIBA 03/2019
1	cordycepinIBA 03/2019
1	endolysinIBA 10/2018
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2018
1	DystrophinIBA 01/2018
1	Antiviral Agents (Antivirals)IBA 07/2017
1	Ribavirin (Virazole)FDA LinkGeneric 07/2017
1	UbiquitinIBA 09/2015
1	Ligases (Synthetase)IBA 09/2015

Therapy/Procedure

5	Therapeutics 01/2022 - 05/2015
4	Drug Therapy (Chemotherapy) 08/2021 - 01/2011
3	Renal Dialysis (Hemodialysis) 11/2015 - 01/2014
2	Mirror Movement Therapy 08/2017 - 06/2017
1	Neoadjuvant Therapy 08/2023
1	Intravenous Injections 09/2020
1	Enteral Nutrition (Feeding, Tube) 10/2017
1	Stents 05/2015
1	Transcranial Magnetic Stimulation 04/2015